Condiciones de SaludLa enfermedad de Graves es un trastorno autoinmune que provoca que la glándula tiroides produzca en exceso hormonas tiroideas—una condición conocida como hipertiroidismo. Es la causa más común de hipertiroidismo y ocurre cuando el sistema inmunológico produce anticuerpos (TRAbs) que estimulan los receptores de la hormona estimulante de la tiroides (TSH), lo que lleva a una producción excesiva de hormonas.
Los sÃntomas resultan de un metabolismo acelerado y pueden incluir:
Pérdida de peso a pesar de un apetito normal o aumentado
Latido cardÃaco rápido o irregular
Ansiedad, irritabilidad o inquietud
Intolerancia al calor y sudoración excesiva
Temblores, especialmente en las manos
Tiroides agrandada (bocio)
Irregularidades menstruales
Fatiga o debilidad muscular
Alteraciones del sueño
Ojos saltones (oftalmopatÃa de Graves)
Adelgazamiento de la piel o cabello quebradizo
La enfermedad de Graves puede afectar a personas de cualquier edad, pero es más común en mujeres menores de 40. A menudo se desarrolla gradualmente, pero puede llevar a complicaciones graves si no se trata, incluyendo problemas cardÃacos, osteoporosis, y tormenta tiroidea—una emergencia que pone en riesgo la vida.
Cuándo consultar a un médico:
Si se experimentan sÃntomas de hipertiroidismo, particularmente pérdida de peso, palpitaciones cardÃacas o cambios oculares visibles, busque evaluación. El diagnóstico implica análisis de sangre (TSH, T3, T4, TRAb), y a veces ecografÃa tiroidea o gammagrafÃa de captación de yodo radiactivo.
Beta-sitosterol is a plant sterol with systematic review evidence for reducing BPH-related urinary symptoms that overlap significantly with OAB, including urgency, frequency, and nocturia. A systematic review of 4 RCTs (n=519 men) found beta-sitosterol improved symptom scores by 4.9 points and peak urinary flow by 3.9 mL/s versus placebo. A 2024 RCT of beta-sitosterol–enriched saw palmetto showed significantly lower Overactive Bladder Symptom Scores.
Capsaicin, the active compound from chili peppers, acts on bladder TRPV1 (vanilloid) receptors on afferent nerves. Intravesical capsaicin instillation desensitizes C-fiber afferents, inhibiting the micturition reflex and increasing bladder capacity. It is reviewed in both the PMC Reviews in Urology (2013) and a 2024 PMC comprehensive OAB review as a recognized intervention for neurogenic detrusor overactivity; however, intravesical application causes local irritation, limiting use.
Intravesical capsaicin has been clinically tested for overactive bladder and neurogenic detrusor overactivity, with evidence of amelioration of urinary frequency and incontinence through TRPV1-mediated C-fiber desensitization. Results are mechanistically well-grounded and supported by human clinical studies.
Open non-randomized clinical studies indicate goldenrod can reduce urgency and painful urination in overactive bladder within 2–4 weeks. In one study of 512 people with chronic overactive bladder taking 425 mg of dry goldenrod extract three times daily, 96% reported improvement. Antispasmodic effects on bladder smooth muscle have been documented in pharmacological research.
Horsetail (Equisetum arvense) is one of the oldest herbal remedies for urinary complaints, traditionally used since ancient Roman and Greek times. As part of the Urox combination (with Crataeva nurvala and Lindera aggregata), it was tested in a phase 2 randomized, double-blind, placebo-controlled trial (n=150) that showed significantly reduced urinary frequency, nocturia, urgency, and incontinence at 8 weeks. The Reviews in Urology (PMC) identified horsetail as one of the key herbal agents studied for OAB.
Magnesium depletion is significantly associated with overactive bladder in large population-based data (NHANES 2005–2018, n=28,621). Mechanistically, magnesium acts as a natural calcium antagonist, and deficiency leads to excess calcium influx causing involuntary detrusor contractions characteristic of OAB. An early clinical study also found magnesium supplementation had a positive effect on urinary frequency, urgency, and voiding difficulty.
Nettle root extract has been studied in RCTs for lower urinary tract symptoms including urinary urgency, frequency, nocturia, and incomplete bladder emptying—the hallmark features of overactive bladder. Products containing nettle root are specifically recommended for symptomatic treatment of urinary incontinence and frequency. The clinical trial database includes conditions directly overlapping with OAB symptom clusters.
Pumpkin seed oil and extract have direct clinical trial evidence for OAB. A 2014 randomized, double-blind, placebo-controlled trial (n=120) of a pumpkin seed and soy germ extract combination found significant reductions in urination frequency, urgency, incontinence, and nocturia versus placebo. An open-label study of 10 g/day pumpkin seed oil over 12 weeks also improved Overactive Bladder Symptom Scores. Pumpkin seed (Cucurbita pepo) is officially ESCOP-monographed for irritable bladder and BPH-related urinary symptoms.
Quercetin is a flavonoid with anti-inflammatory properties shown to benefit bladder pain and interstitial cystitis (IC), conditions that overlap with OAB. A clinical trial (Katske et al., Tech Urol 2001) found quercetin supplementation improved IC symptoms at 4 weeks. Naturopathic guidelines reference quercetin for bladder inflammation underlying OAB. However, no placebo-controlled RCT has tested quercetin as a standalone treatment specifically for OAB.
Reishi mushroom (Ganoderma lucidum) has been formally tested in a randomized, double-blind, placebo-controlled trial (n=88 men) for lower urinary tract symptoms. Treatment with 6 mg/day of G. lucidum extract for 12 weeks produced significantly better International Prostate Symptom Score improvement versus placebo (mean difference −1.18 points; P<0.0001). G. lucidum also shows potent 5α-reductase inhibitory activity, reducing prostate-driven bladder overactivity.
Saw palmetto berry extract (320 mg/day) has been evaluated in clinical trials for OAB-related urinary symptoms in both men and women. A 2020 RCT in 44 men and a 2022 multicenter RCT in 75 women both reported significant reductions in daytime frequency, urgency, and nocturia on the Overactive Bladder Symptom Score. A 2024 Cochrane review found limited overall benefit for BPH, but saw palmetto shows specific OAB-pathway activity via muscarinic and vanilloid receptor binding.
Soy isoflavones (primarily genistein and daidzein) have been studied for OAB via multiple mechanisms. A 2014 RCT (n=120) of a pumpkin seed + soy germ extract combination significantly reduced urination frequency, urgency, and nocturia versus placebo. A cross-sectional study of 2,000 elderly Chinese men found dietary soy isoflavone intake was linked to a lower risk of lower urinary tract symptoms. In vitro, genistein and daidzein dose-dependently decrease detrusor contractions.
Vitamin D deficiency is strongly linked to OAB, with a meta-analysis (PubMed PMID 37195440) finding vitamin D–deficient individuals had more than 4-fold higher odds of OAB and 30% higher odds of urinary incontinence. Vitamin D supplementation reduced urinary incontinence risk by 66% in the same meta-analysis. Vitamin D receptors are present in bladder muscle and pelvic floor tissue, and clinical supplementation has been shown to improve urinary symptoms.
Vitamin D3 (cholecalciferol) is the primary supplemental form studied in relation to overactive bladder and urinary incontinence. A meta-analysis found vitamin D deficiency increased OAB risk more than 4-fold, and supplementation reduced urinary incontinence risk by 66%. Vitamin D3 receptors exist in bladder muscle and pelvic floor tissue, and correcting deficiency has shown clinical urinary symptom improvements.
Volver